Donanemab in Early Alzheimer's Disease

Area of Science:

• Neurology
• Immunotherapy
• Neurodegenerative Diseases

Background:

• Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) peptide accumulation.
• Donanemab is an investigational antibody targeting modified deposited Aβ for early AD treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of donanemab in early symptomatic Alzheimer's disease.
• To assess donanemab's impact on cognitive and functional measures and amyloid/tau burden.

Main Methods:

• Phase 2 trial with 257 early AD patients with confirmed tau and amyloid deposition.
• Randomized 1:1 assignment to intravenous donanemab or placebo every 4 weeks for up to 72 weeks.
• Primary outcome: change in Integrated Alzheimer's Disease Rating Scale (iADRS) score at 76 weeks.

Main Results:

• Donanemab showed a statistically significant improvement in the primary iADRS score compared to placebo (difference of 3.20; P=0.04).
• Secondary outcome measures showed mixed results, with no substantial differences in most.
• Donanemab significantly reduced amyloid plaque levels and global tau load, with reported amyloid-related imaging abnormalities.

Conclusions:

• Donanemab demonstrated improved composite scores for cognition and daily living activities versus placebo in early AD.
• Results for secondary outcomes were mixed, necessitating further investigation.
• Larger, longer trials are required to fully establish donanemab's efficacy and safety profile in Alzheimer's disease.